Business Wire

GA-SYNCRON

27.9.2021 15:04:10 CEST | Business Wire | Press release

Share
Syncron Named a Leader for B2B Price Optimization and Management in IDC MarketScape Report

Syncron, the largest privately-owned global leader in intelligent SaaS solutions dedicated to End-to-End Continuous Service LifeCycle Management, announced today that it has been named a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment (doc # US46742021, September 2021). Syncron is providing a complimentary excerpt of the IDC MarketScape report here .

The IDC MarketScape vendor assessment model is an important competitive evaluation and scoring of the SaaS-based business-to-business price optimization and management solution suppliers available in the global market. According to the IDC MarketScape the nine vendors covered in the IDC MarketScape represent the front-runners and the vendors most representative of any given B2B PO&M application buyer's selection short list. IDC’s research methodology uses a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear, customer influenced framework, in which the product and service offerings, capabilities, and strategies, and current and future market success factors can be meaningfully compared.

The IDC MarketScape report’s profile stated, “After a thorough evaluation of Syncron's offerings and capabilities, IDC has positioned the company in the Leaders category within this 2021 IDC MarketScape for B2B price optimization and management applications.” The report also states that “Syncron has greatly expanded its vision to be the end-to-end service management provider. This is an integrated suite of solutions to optimize inventory, price, and uptime for aftermarket parts and service for B2B or retail-focused companies. This enables Syncron to optimize both price and cost.”

The research positioned Syncron as a leader based on the flexible capabilities and intuitive functionality of Syncron Price, and the company’s deep understanding of the aftermarket industry globally.

The report states that companies should consider Syncron when they’re in the aftermarket service industry and need an end-to-end service management solution with integrated pricing. The IDC MarketScape vendor assessment also recognized three of Syncron’s strengths:

Deep understanding of aftermarket service management: Syncron Price benefits from Syncron Inventory and the company's deep institutional knowledge of the cost side of the equation to manage profit when pricing inventory that is deployed around the world, including location (delivery time, taxes, tariffs), age, and scarcity/replacement value. Customers highly appreciated this experience to set up personalized pricing for specialty parts and kits.

Ease of Use: Customers highly rated Syncron for how easy the product was to learn and use. They liked that it had initiative workflows that were "one to two clicks away from done."

Pricing Agility: Syncron makes it easy to segment and manage huge numbers of parts. Customers liked the ML-driven segmentation workflow that made segmentation easy to implement and gave the user the best choices of which segment the product should be placed in. One customer was managing 300,000 parts with one person while being able to reprice each on a far more regular basis with greater profit.

“Syncron combines its deep knowledge of the global aftermarket industries, with robust solution capabilities, and expert services to substantively increase the efficiency and profitability of an OEM's aftermarket businesses,” says Mark Thomason, Research Director, IDC. “Syncron Price enables manufacturers, dealers, and suppliers to automate and optimize dynamic pricing capabilities, quickly and globally. By leveraging artificial intelligence and machine learning, Syncron Price can segment highly complex product lists and identify otherwise unseen revenue uplift and margin opportunities.”

“At Syncron, we’re committed to empower the world’s leading manufacturers and distributors to drive profitable business and competitive advantage by providing intelligent and connected service experience solutions. We are deeply honored the IDC MarketScape named Syncron a Leader for the Price Optimization and Management category. This acknowledgement follows similar IDC MarketScape recognitions of Syncron and its newly acquired company, Mize, in the areas of Field Service Management (FSM)1 , Service Parts Management (SPM), and Warranty Contract Management (WCM)2 ,” said Dr. Friedrich Neumeyer, CEO of Syncron. “Being recognized as a leader in multiple strategic categories by the IDC MarketScape is validation that our significant innovation investments in AI and ML innovation, user experience, architectural extensibility, scalability, security, and platform are quickly paying dividends. It also echoes Syncron’s nonstop passion and commitment and ability to execute our customers’ success.”

To learn more about Syncron Price, www.syncron.com/price .

About Syncron

Syncron accelerates leading manufacturers and distributors to capitalize on the world's new service economy. We improve aftermarket business profitability, optimize working capital, increase customer loyalty, and enable our customer’s ability to transition successfully to future service-driven business models. With our industry-leading investments in AI and ML, Syncron offers the first, innovative, customer-endorsed, and complete end-to-end intelligent Service Lifecycle Management solution portfolio. Syncron’s offer encompasses leadership solutions such as: service parts inventory, price, equipment uptime, warranty, service contract, and field service management. Delivered on Syncron’s Connected Service Experience (CSX) platform, our solutions offer our customers competitive differentiation through exceptional aftermarket service experiences, while simultaneously driving significant revenue and profit improvements into a manufacturer or distributor’s business. It is no secret that world's top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more information, visit syncron.com .


1 IDC MarketScape: Worldwide Manufacturing Field Service Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC #US44408719, November 2019

2 IDC MarketScape: Worldwide Manufacturing Warranty and Service Contract Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC# US44408619 December 2019

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye